Ticker brief
PCRX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
28
authors 14d
21
crowd 14d
-0.3σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-08 → 2026-10-15 · now +0.35 (−1 bearish … +1 bullish)
Who spoke21
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 6 | +0.50 |
| @FwdQuarter | C | · | 2 | +0.50 |
| @ClassicRoy | C | -1.10 | 2 | +0.22 |
| @CHItrader | B | -0.22 | 1 | +0.50 |
| @cfromhertz | B | -0.96 | 1 | +0.50 |
| @OMillionaires | C | -0.85 | 1 | +0.50 |
| @MartyChargin | C | -0.56 | 1 | +0.50 |
| @OTR444 | C | +0.13 | 1 | +0.25 |
| @WSJ | A | -0.25 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @fwpharma | B | -1.91 | 1 | +0.50 |
| @SpartanTrading | C | +1.30 | 1 | +0.00 |
| @Tickeron | C | +1.53 | 1 | +0.50 |
| @TWFeditor | C | -1.36 | 1 | -0.35 |
| @OptionsFlowBoss | C | · | 1 | +0.50 |
| @Analytica_X | B | -0.29 | 1 | +0.50 |
| @InvestorIdeas | C | -0.26 | 1 | +0.50 |
| @DarthDividend23 | C | +0.32 | 1 | +0.00 |
| @BarbarianCap | B | +1.97 | 1 | +0.50 |
| @financespotnews | C | +0.40 | 1 | +0.35 |
| @WallStDiaries | C | +0.67 | 1 | +0.50 |
Recent signals28of 28 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @ClassicRoy | +0.35 | Identifies three stocks as major breakouts. | · | tweet ↗ |
| 2026-10-11 | @WallStDiaries | +0.50 | Viatris is acquiring Pacira for $36.50 per share in a $1.65 billion cash deal. | · | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.50 | Weekly biotech event roundup covering acquisition, clinical data, FDA status, licensing, and a trial miss. | · | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.50 | Summarizes large biotech moves tied to a buyout and trial outcomes, then flags upcoming studies. | · | tweet ↗ |
| 2026-10-09 | @financespotnews | +0.35 | Reports Pacira rising 44.1% amid concentrated biotech volatility and sector M&A rotation. | · | tweet ↗ |
| 2026-10-08 | @BarbarianCap | +0.50 | Viatris will acquire Pacira BioSciences for $1.65 billion. | · | tweet ↗ |
| 2026-10-08 | @DarthDividend23 | +0.00 | Lists five top market movers sourced from Stock Analysis. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.50 | Reports PCRX rising about 44% premarket on VTRS buyout news. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.50 | Viatris will acquire Pacira for $36.50 cash per share at a $1.65B equity value and 44.8% premium. | · | tweet ↗ |
| 2026-10-08 | @InvestorIdeas | +0.50 | Viatris agreed to acquire Pacira for $36.50 per share in cash at a $1.65B equity value. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.50 | Summarizes large biotech moves and lists upcoming Phase 2 and Phase 3 catalysts. | · | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.50 | Biotech roundup reports acquisition, trial approval, study and financing events. | · | tweet ↗ |
| 2026-10-08 | @ClassicRoy | +0.10 | Ranks names by unusually high standard-deviation gains versus the prior 20 days. | · | tweet ↗ |
| 2026-10-08 | @Analytica_X | +0.50 | Explains Viatris's $1.65B cash acquisition of Pacira at $36.50 per share and its strategic rationale. | · | tweet ↗ |
| 2026-10-08 | @OptionsFlowBoss | +0.50 | Reports unusually bullish options volume at 3.5x, 10x and 200x normal levels. | · | tweet ↗ |
| 2026-10-08 | @TWFeditor | -0.35 | Notes a fund had been accumulating PCRX before today's large exit. | · | tweet ↗ |
| 2026-10-08 | @Tickeron | +0.50 | Viatris agreed to acquire Pacira for $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @FwdQuarter | +0.50 | VTRS agreed to acquire PCRX for $1.65B in an all-cash tender. | · | tweet ↗ |
| 2026-10-08 | @SpartanTrading | +0.00 | Lists six premarket tickers on watch without directional entries. | · | tweet ↗ |
| 2026-10-08 | @fwpharma | +0.50 | Viatris agreed to acquire Pacira for $1.65B | · | tweet ↗ |
| 2026-10-08 | @OpenOutcrier | +0.50 | Viatris will acquire Pacira BioSciences for $1.65B, or $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @WSJ | +0.50 | Viatris agreed to acquire Pacira BioSciences for $1.65B. | · | tweet ↗ |
| 2026-10-08 | @FwdQuarter | +0.50 | VTRS agreed to acquire PCRX for $1.65B cash at $36.50 per share. | · | tweet ↗ |
| 2026-10-08 | @OTR444 | +0.25 | Provides an October 8 momentum watch list with market-cap and company-event notes. | · | tweet ↗ |
| 2026-10-08 | @MartyChargin | +0.50 | Viatris agrees to acquire Pacira for $36.50 cash per share, valuing equity at $1.65B. | · | tweet ↗ |
| 2026-10-08 | @OMillionaires | +0.50 | VTRS will acquire PCRX for $36.50 per share in cash, valuing it at $1.65B. | · | tweet ↗ |
| 2026-10-08 | @cfromhertz | +0.50 | Viatris agrees to acquire Pacira for $1.65B, or $36.50 per share in cash. | · | tweet ↗ |
| 2026-10-08 | @CHItrader | +0.50 | Viatris agrees to acquire Pacira Biosciences for $1.65B in equity value. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.